AIFF — Firefly Neuroscience Income Statement
0.000.00%
Last trade - 00:00- $33.31m
- $30.57m
- $1.14m
Annual income statement for Firefly Neuroscience, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 15 | 11 | 7.98 | 0.108 | 1.14 |
| Cost of Revenue | |||||
| Gross Profit | 3.62 | 2.86 | 2.61 | — | 0.645 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 17.2 | 16.4 | 9.77 | 10.2 | 11.4 |
| Operating Profit | -2.18 | -5.42 | -1.79 | -10.1 | -10.2 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -2.2 | -5.49 | -1.5 | -10.5 | -19.9 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1.13 | -6.31 | -1.45 | -10.5 | -19.9 |
| Equity in Affiliates | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -1.13 | -17.8 | -2.03 | -10.5 | -19.9 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.13 | -17.8 | -2.03 | -10.5 | -24.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.23 | -9.71 | -3.34 | -1.51 | -1.89 |